Tag Archives: EP Vantage

ASCO, aka The Oncology Super Bowl for Biotechs, sends stocks in every direction

Steve’s Take: As another jam-packed annual meeting of the American Society of Clinical Oncology in Chicago wrapped up on Tuesday (June 6, 2017), with some 38,000 oncologists gathering together at… Read more »

German Merck, flying under Street’s radar, gets no respect; but not for long

Steve’s Take: Wall Street analysts are perhaps familiar with the history behind the two Pharma powerhouses, US-based Merck & Co., and Germany-based Merck KgaA. Until recently, however, I only had… Read more »

Allergan wraps up 2016 M&A with LifeCell buy for $2.9 billion; analysts lavish kudos all around

Dublin-based Allergan said on December 19, 2016 it would buy LifeCell, a regenerative medicine unit owned by privately held Acelity LP (San Antonio TX), for $2.9 billion in cash, bringing… Read more »